Core Insights - PLAY experienced a significant decrease in passenger numbers, carrying 124,286 passengers in August 2025 compared to 187,960 in August 2024, primarily due to a strategic shift in fleet deployment and ACMI leasing agreements [1] - Despite the reduced capacity, the load factor was 89.6%, slightly down from 91.6% in August 2024, reflecting the transition from a VIA-focused network to a leisure-focused model, which typically has lower load factors but higher yields [2] - The unit revenue for August reached its highest level ever for the month, indicating the success of the strategic shift towards leisure routes [2] - Operational performance remained strong with an on-time performance of 89.0%, compared to 91.5% in August 2024, showcasing the company's commitment to operational efficiency [3] Financing and Growth - In August, Fly Play hf. completed the issuance of a two-year convertible bond amounting to approximately USD 23 million (over ISK 2.8 billion), with initial commitments of USD 20 million [4] - The increased demand for the bond offering reflects investor confidence in the company and strengthens its operational foundation, allowing for a focus on profitable projects and growth [5] Leadership Perspective - The CEO of PLAY highlighted the strong operational results and the successful adaptation of operations, emphasizing the focus on point-to-point leisure destinations and the achievement of the highest unit revenue for August [6]

Core Insights - ALK announced the acceptance of real-world evidence regarding the clinical performance of the nasal adrenaline spray neffy for patients experiencing anaphylaxis during oral food challenges and allergen immunotherapy, marking a significant milestone in its clinical evaluation [1][2]. Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma treatments, headquartered in Hørsholm, Denmark, employing around 2,800 people and listed on Nasdaq Copenhagen [6]. Product Information - Neffy is a ready-to-use, needle-free nasal adrenaline spray developed by ARS Pharmaceuticals, Inc., approved for emergency treatment of anaphylaxis. ALK holds exclusive global commercialization rights for neffy, except in the USA, Australia, New Zealand, Japan, and China [3][6]. - The product was launched in Germany in June 2025, with plans for additional launches in other EU markets by the end of the year [3]. Clinical Performance - The analysis indicated that 89.2% of 545 patients treated with a single dose of neffy were successfully managed, with 10.8% requiring a second dose. This effectiveness aligns closely with historical data for adrenaline injections, which report a success rate of 88.9% [2][4]. - The observational analysis was based on data from healthcare providers in the neffy experience program, which included 301 providers and 545 treated patients as of March 2025 [4].

Core Viewpoint - CoinShares International Limited is merging with Vine Hill Capital Investment Corp. and Odysseus Holdings to facilitate a change of listing venue from Nasdaq Stockholm to the Nasdaq Stock Market in the U.S., valuing CoinShares at approximately USD 1.2 billion, which represents a premium of about 30.6% compared to its last closing price on Nasdaq Stockholm [1][10][13]. Transaction Overview - The merger involves a court-sanctioned Scheme of Arrangement under Jersey Law, allowing CoinShares shareholders to exchange their shares for ordinary shares in Odysseus Holdings [2][17]. - The completion of the Transaction is expected to occur on 17 December 2025, subject to various conditions including shareholder approvals and regulatory clearances [1][30][47]. Valuation and Consideration - The total consideration for CoinShares' shareholders is approximately SEK 11.3 billion or USD 1.2 billion, translating to about SEK 173.2 per ordinary share, reflecting a premium of approximately 30.6% over the last trading price [1][10][13]. - Each CoinShares ordinary share will be exchanged for approximately 1.8116 ordinary shares of Odysseus Holdings based on the Equity Value Per Share [3][17]. Strategic Rationale - The Transaction aims to reposition CoinShares within the U.S. capital markets, enhancing access to institutional investors and improving research coverage, which is expected to support CoinShares' growth ambitions in the U.S. marketplace [9][11]. - CoinShares has been limited by its current listing characteristics, including low trading volumes and restricted analyst coverage, which the merger seeks to address [8][9]. Private Placement - CoinShares plans to conduct a private placement of 5,000,000 ordinary shares at USD 10.0 per share, raising approximately USD 50.0 million in gross proceeds, with an additional allocation of 1,666,667 shares to the Private Placement Investor [1][55]. - The private placement is intended to support CoinShares' growth strategy and will result in a dilution of approximately 9.0% of the total ordinary shares [58]. Shareholder Support - Key shareholders, representing approximately 87.7% of CoinShares' shares, have agreed to vote in favor of the Transaction and not to take actions that may impair its completion [42][39]. - The Board of Directors of CoinShares has obtained a fairness opinion indicating that the Transaction consideration is fair from a financial perspective [39][40]. Timeline - The indicative timetable includes the initiation of the Scheme of Arrangement on 5 November 2025, with the Court Meeting and Special Meeting expected on or about 8 December 2025, and the completion of the Transaction anticipated on 17 December 2025 [47][48].

Core Insights - HOPE Therapeutics, Inc. has completed the acquisition of Dura Medical, which will enhance its service offerings across more than 8 locations in West Florida [1][9] - Dura Medical specializes in treating depression, PTSD, and chronic pain using advanced interventional psychiatry techniques [2][9] - The acquisition aims to expand HOPE's network and improve access to mental health services, particularly for veterans [3][5][9] Company Overview - Dura Medical was founded in 2018 and operates in Naples and Ft. Myers, Florida, focusing on a precision approach to mental health treatment [2][9] - The company utilizes innovative therapies such as Ketamine Infusion Therapy and Transcranial Magnetic Stimulation (TMS) to provide comprehensive care [2][9] - Dura Medical is revenue-generating and EBITDA positive, indicating a strong financial position [1] Strategic Goals - The combined entity aims to treat over 10,000 individuals by 2026, reflecting a commitment to reducing suicide rates in the community [5] - HOPE Therapeutics plans to leverage Dura's expertise and expand its network throughout Florida [6][9] - The appointment of Stephen Durand as Director of Florida Clinic Operations is expected to enhance operational leadership and patient care [4][6] Industry Context - The mental health crisis in the U.S. is significant, with over 13 million Americans contemplating suicide annually [2] - Dura Medical's participation in the Veterans Affairs Community Cares Network is crucial for providing mental health support to veterans, who face high rates of suicide [3][9] - The integration of psychedelic medications with traditional therapies represents a growing trend in the treatment of severe mental health disorders [6]

A new industry standard for faster, more precise and confident decision-making in private capital marketsNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Kroll, the leading independent provider of global financial and risk advisory solutions, and StepStone Group (Nasdaq: STEP), a global private markets solutions provider, today announced the launch of the Kroll StepStone Private Credit Benchmarks (Benchmarks). A new industry standard, the Benchmarks enable more robust and rigorous valuation and provide an unmat ...

New scoring mode and integrated Singing Machine microphone coming soonMONTREAL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Stingray Group (TSX: RAY. A; RAY.B), an industry leader in music and video content distribution, business services, and advertising solutions, today announced the launch of an advanced karaoke experience for BYD vehicles. The new feature will initially be available for most of the Ocean and Dynasty series models and will be extended to Denza models in the near future. This launch marks the debu ...

LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the America ...

LAS VEGAS, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today opened U.S. pre-orders for the new IQ9N-3P™ Commercial Microinverter. This is Enphase’s first microinverter powered by advanced gallium nitride (GaN) technology and designed for three-phase 480Y/277 V (wye) grid configurations, without using external transformers. The IQ9N-3P Commercial Microinverter sim ...

Washington-based MLS contracts to make FOREWARN services available for its 1,800+ real estate professional members to promote proactive agent safetyBOCA RATON, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Pacific Regional Multiple Listing Service (“PACMLS”) will offer FOREWARN® services to its 1,800+ members it serves which include Tri-City Association of RE ...

Daniel M. Wagner presents at HC Wainwright and launches AGP and Northland roadshows to broaden investor engagementNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), a leader in proprietary AI-powered commerce solutions, today announced that CEO Daniel M. Wagner will present at the HC Wainwright Global Tech Investor Conference this week, highlighting the company’s growth trajectory, AI innovation, and expanding market opportunity. Building on this visibility, Rezolve is also commencing a ...